Tiffany Villamarin
Adult Health · Norwalk, CTNPI 1477265635
Payments from drug & device makers
Across 168 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$401
- AbbVie$332
- Incyte Corporation$254
- Pfizer$226
- AstraZeneca$223
- Takeda Pharmaceuticals U.S.A., Inc.$172
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,45495%
- Education$1855%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 23 | $401 |
| AbbVie | 12 | $332 |
| Incyte Corporation | 10 | $254 |
| Pfizer | 12 | $226 |
| AstraZeneca(2 entities) | 10 | $223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $172 |
| Eisai Inc. | 7 | $171 |
| Novartis | 6 | $169 |
| Rigel Pharmaceuticals, Inc. | 9 | $163 |
| Regeneron Healthcare Solutions, Inc. | 6 | $117 |
| E.r. Squibb & Sons, L.L.C. | 5 | $112 |
| Daiichi Sankyo Inc. | 6 | $108 |
| Johnson & Johnson | 5 | $103 |
| Lilly USA, LLC | 3 | $83 |
| Mirati Therapeutics, Inc. | 4 | $81 |
| Genentech USA, Inc. | 3 | $76 |
| Amgen | 3 | $75 |
| Astellas Pharma US Inc | 3 | $75 |
| Array Biopharma Inc | 3 | $65 |
| ADC Therapeutics America, Inc. | 2 | $54 |
| EMD Serono, Inc. | 2 | $53 |
| Jazz Pharmaceuticals Inc. | 3 | $52 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $46 |
| Servier Pharmaceuticals LLC | 2 | $45 |
| AVEO Pharmaceuticals, Inc. | 2 | $44 |
| Legend Biotech USA Inc. | 2 | $35 |
| Bayer | 2 | $35 |
| Sanofi | 1 | $35 |
| Puma Biotechnology, Inc. | 2 | $28 |
| Pharmaessentia USA Corporation | 1 | $28 |
| GSK | 1 | $24 |
| Gilead | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Agios Pharmaceuticals, Inc. | 1 | $20 |
| Stemline Therapeutics Inc. | 1 | $20 |
| Coherus Oncology, Inc. | 1 | $18 |
| Karyopharm Therapeutics Inc. | 1 | $18 |
| Foundation Medicine, Inc. | 1 | $17 |
| Merck | 1 | $15 |
How this compares
$3,639 in reported general payments places this provider in the 80th percentile of 418 adult health providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 30 | $423,629 |
| ImbruvicaIbrutinib | 23 | $361,988 |
| VenclextaVenetoclax | 25 | $284,019 |
| XtandiEnzalutamide | 14 | $254,897 |
| RevlimidLenalidomide | 13 | $237,979 |
| JaypircaPirtobrutinib | 11 | $219,113 |
| BrukinsaZanubrutinib | 18 | $192,803 |
| Abiraterone Acetate | 66 | $72,193 |
| ZenpepLipase/Protease/Amylase | 25 | $35,330 |
| EliquisApixaban | 32 | $18,896 |
| CreonLipase/Protease/Amylase | 11 | $17,040 |
| Ondansetron Hcl | 52 | $1,484 |
| Prochlorperazine Maleate | 44 | $1,178 |
| Prednisone | 62 | $542 |
| Letrozole | 17 | $490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $46 | $361,98823 claims |
| AbbVieVenclexta, Creon | $332 | $301,05936 claims |
| Astellas Pharma US IncXtandi | $75 | $254,89714 claims |
| Bristol Myers SquibbRevlimid | $401 | $237,97913 claims |
| Lilly USA, LLCJaypirca | $83 | $219,11311 claims |
| PfizerEliquis | $226 | $18,89632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 418 adult health providers in Connecticut.
Other adult health in Norwalk
- Leah EhleManchester$418K
- Laura MulkaWethersfield$306K
- Gretchen MichaelsonSouth Windsor$169K
- Kimberly RyanWethersfield$74K
- Kathryn JackMeriden$67K
- Lynn RapsilberTorrington$52K
- Genice NelsonFarmington$36K
- Andrea LauterNew London$32K
- Megan CarlucciManchester$28K
- Kellie HaleNew Haven$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.